Randomized Phase II Study of IMMU-132 Alone or in Combination With Carboplatin in Patients With Relapsed/Refractory Triple-Negative Breast Cancer

Trial Profile

Randomized Phase II Study of IMMU-132 Alone or in Combination With Carboplatin in Patients With Relapsed/Refractory Triple-Negative Breast Cancer

Recruiting
Phase of Trial: Phase II

Latest Information Update: 08 Feb 2018

At a glance

  • Drugs Sacituzumab govitecan (Primary) ; Carboplatin
  • Indications Breast cancer
  • Focus Therapeutic Use
  • Sponsors Immunomedics
  • Most Recent Events

    • 08 Feb 2018 According to an Immunomedics media release, BLA submission for Sacituzumab Govitecan in metastatic triple-negative breast cancer is expected in May 2018.
    • 08 Feb 2018 According to an Immunomedics media release, updated results from 110 patients were presented at the San Antonio Breast Cancer Symposium 2017.
    • 13 Nov 2017 According to an Immunomedics media release, BLA submission planned in the first quarter of 2018 to the FDA for accelerated approval as third-line treatment for mTNBC.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top